Knowledge Center
Article / 2013
Optimising Quality by Design in Bulk Powders and Solid Dosage
Source:
Pharmaceutical Technology Europe, September 2013
The changing development paradigm resulting from the US Food and Drug Administration’s quality-by-design (QbD) initiative and International Conference on Harmonisation (ICH) guidelines requires increased process understanding of the drug substance and drug product throughout development and manufacturing. A lack of information can result in delays in regulatory approval and higher costs. Applying QbD principles leads to greater process understanding, facilitates regulatory approval and streamlines postapproval changes. Case studies on the manufacture of a bulk powder and the development of a tablet show the application of QbD principles, including defining critical quality attributes, implementing risk assessment, optimising process development, developing a design space and performing a criticality analysis.
Related links
Also in the Knowledge Center
Poster / May 03, 2022
Use of PAT tools in the development, monitor and control of continuous manufacturing processes
Read more
Scientific Article
Poster / May 03, 2022
Enhancing the “right first time” concept in Continuous Manufacturing – Development strategy
Read more
Scientific Article
Scientific Article